Assistant Professor Basic Pharmaceutical Sciences
4024 Congdon Hall
PhD Molecular and Cellular Pharmacology, 2013
University of Miami – Miller School of Medicine
B.S. Pharmacology and Toxicology, 2006
University of Wisconsin – School of Pharmacy
Postdoctoral Fellow – Cancer Biology, 2014-2017
Research Associate – Cancer Biology, 2017-2019
Wake Forest University – School of Medicine
Cancer is an inherently heterogeneous disease, and even in the best-case scenarios, it is ostensibly difficult to treat. Even when standard of care is employed, cancers often do not respond or acquire resistance to therapy and continue to grow, spread and ultimately lead to life-threatening conditions. Dr. Fahrenholtz’s lab seeks to understand the genetic and molecular mechanisms that drive both difficult-to-treat cancers and cases of acquired resistance to therapy. Using this information, we are developing new ways to stratify patients and treat cancer using rational combinations of nanomedicine and conventional therapies. The Fahrenholtz lab is currently investigating several combination therapies that may improve patient outcomes while reducing both required dose and off-target effects. Active projects include the use of silver nanoparticles in combination with small molecule inhibitors for the treatment of ovarian cancer, and establishing high-throughput methods for the derivation and screening of treatment-refractory clones.
- Swanner J, Fahrenholtz CD, Tenvooren I, Bernish BW, Sears JJ, Hooker A, Furdui C, Alli E, Li W, Donati GL, Cook KL, Vidi PA, Singh R. 2019. Silver nanoparticles selectively treat triple negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo. FASEB Bioadvances. Epub Sep 2019.
- Zhao N, Peacock SO, Lo CH, Heidman LM, Rice MA, Fahrenholtz CD, Greene AM, Magani F, Copello VA, Martinez MJ, Zhang Y, Daaka Y, Lynch CC, Burnstein KL. 2019. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. Sci Transl Med. June 26; 11(498). PMID: 31243151.
- Fahrenholtz CD, Swanner J, Ramirez-Perez M, Singh R. 2017. Heterogeneous responses of ovarian cancer cells to silver nanoparticles as a single agent and in combination with cisplatin. J Nanomater. Article ID 5107485. PMID: 30034459
- Fahrenholtz CD, Ding S, Bernish BW, Wright ML, Zheng Y, Gross MD, Bierbach U, Singh R. 2016. Design and cellular studies of a carbon nanotube-based delivery system for a hybrid platinum-acridine anticancer agent. J Inorg Biochem. 165: 170-180. PMID: 27496614
- Fahrenholtz CD, Hadimani M, King SB, Torti SV, Singh RN. 2015. Targeting breast cancer with sugar-coated carbon nanotubes. Nanomedicine (Lond). 10(16):2481-97. PMID:26296098
- Fahrenholtz CD, Greene AM, Beltran PJ, Burnstein KL. 2014. A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells. Oncotarget. 5(19): 9007-9021. PMID: 25344862
- Fahrenholtz CD, Rick FG, Garcia MI, Zarandi M, Cai RZ, Block NL, Schally AV, Burnstein KL. 2014. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant prostate cancer. Proc Nat Acad Sci. 111(3): 1084-1809. PMID: 24395797
- Fahrenholtz CD, Beltran PJ, Burnstein KL. 2013. Targeting IGF-1R with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts. Mol Cancer Ther. 12(4); 394-404. PMID: 23348048
Complete Publications List: